



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Andrew Emili,  
✉ aemili@abu.edu

RECEIVED 24 January 2024  
ACCEPTED 25 January 2024  
PUBLISHED 09 February 2024

## CITATION

Lin W, Mousavi F, Blum BC, Heckendorf CF, Moore J, Lampl N, McComb M, Kotelnikov S, Yin W, Rabhi N, Layne MD, Kozakov D, Chitalia VC and Emili A (2024), Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease. *Front. Pharmacol.* 15:1376058. doi: 10.3389/fphar.2024.1376058

## COPYRIGHT

© 2024 Lin, Mousavi, Blum, Heckendorf, Moore, Lampl, McComb, Kotelnikov, Yin, Rabhi, Layne, Kozakov, Chitalia and Emili. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease

Weiwei Lin<sup>1,2</sup>, Fatemeh Mousavi<sup>1</sup>, Benjamin C. Blum<sup>1,2</sup>, Christian F Heckendorf<sup>1,2</sup>, Jarrod Moore<sup>1,2</sup>, Noah Lampl<sup>1,2</sup>, Mark McComb<sup>1,2</sup>, Sergei Kotelnikov<sup>3</sup>, Wenqing Yin<sup>4</sup>, Nabil Rabhi<sup>2</sup>, Matthew D. Layne<sup>2</sup>, Dima Kozakov<sup>3</sup>, Vipul C. Chitalia<sup>4,5,6</sup> and Andrew Emili<sup>1,2,7\*</sup>

<sup>1</sup>Center for Network Systems Biology, Boston University, Boston, MA, United States, <sup>2</sup>Department of Biochemistry, Boston University School of Medicine, Boston, MA, United States, <sup>3</sup>Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, United States, <sup>4</sup>Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, United States, <sup>5</sup>Veterans Affairs Boston Healthcare System, Boston, MA, United States, <sup>6</sup>Institute of Medical Engineering and Sciences, Massachusetts Institute of Technology, Cambridge, MA, United States, <sup>7</sup>Department of Biology, Boston University, Boston, MA, United States

## KEYWORDS

metabolomics, proteomics, nLC-MS/MS, ESKD, integrated omics

## A Corrigendum on Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease

by Lin W, Mousavi F, Blum BC, Heckendorf CF, Moore J, Lampl N, McComb M, Kotelnikov S, Yin W, Rabhi N, Layne MD, Kozakov D, Chitalia VC and Emili A (2023). *Front. Pharmacol.* 14:1243505. doi: 10.3389/fphar.2023.1243505

In the published article, there was an error in the **Funding** statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.”

The correct **Funding** statement appears below.

“This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.